These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16270533)

  • 1. Level of 5-fluorodeoxyuridine 5'-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1. A preliminary study.
    Yamamoto S; Kubota K
    J Exp Clin Cancer Res; 2005 Sep; 24(3):457-62. PubMed ID: 16270533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
    Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
    Une Y; Ito Y; Ogasawara K; Nagafuchi E; Matsuoka S; Misawa K; Sato N; Nakajima Y; Uchino J
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3153-9. PubMed ID: 2551251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug concentration in cancerous large bowel tissue and thymidylate synthase inhibition rate after administration of tegafur and UFT].
    Futami K; Arima S; Yoshimura S; Okamoto T; Yamasaki K; Koto T; Yamasaki S; Kawahara K; Ikuno T
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):215-20. PubMed ID: 1992915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].
    Uyama R; Yoshizawa Y; Tajiri T; Endo Y; Mitsuya T; Sanada Y
    Gan To Kagaku Ryoho; 2006 May; 33(5):625-9. PubMed ID: 16685161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of low-dose CDDP/5-FU therapy on thymidylate synthase content].
    Kosaka T; Ueshige N; Sugaya J; Nakano Y; Takashima S
    Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():450-3. PubMed ID: 9589051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
    Spears CP; Gustavsson BG; Berne M; Frösing R; Bernstein L; Hayes AA
    Cancer Res; 1988 Oct; 48(20):5894-900. PubMed ID: 3167844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
    Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
    Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thymidylate synthase activity after preoperative administration of 5-FU in patients with gastric or colorectal cancer].
    Arima S; Tachikawa D; Kawahara K; Futami K
    Gan To Kagaku Ryoho; 2000 May; 27(5):703-10. PubMed ID: 10832438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
    Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
    Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
    Harada K; Kawashima Y; Yoshida H; Sato M
    Oncol Rep; 2006 Jun; 15(6):1417-23. PubMed ID: 16685374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer.
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Higuchi A; Satoh A; Mizumoto T; Hamamoto R
    Anticancer Res; 1999; 19(6C):5621-6. PubMed ID: 10697629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
    Shimoda M; Sawada T; Kubota K
    Pathobiology; 2009; 76(4):193-8. PubMed ID: 19571608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
    Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
    Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
    Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
    Miyamoto S; Boku N; Ohtsu A; Yoshida S; Ochiai A; Okabe H; Fukushima M
    Int J Oncol; 2000 Oct; 17(4):653-8. PubMed ID: 10995874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
    Kai K; Kitajima Y; Hiraki M; Satoh S; Tanaka M; Nakafusa Y; Tokunaga O; Miyazaki K
    Cancer Lett; 2007 Dec; 258(1):45-54. PubMed ID: 17892912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
    Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
    Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
    Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.